Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis

Journal of the American Academy of Dermatology

Volumn 72, Issue 4, 2015, Pages 589-598

  D'Souza, Logan S ^a   Payette, Michael J ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

cost effectiveness; Key words biologics; methotrexate; phototherapy; psoriasis; psoriasis treatment

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; PSORALEN; USTEKINUMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL SOCIETY; NARROWBAND ULTRAVIOLET B LIGHT PHOTOTHERAPY; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PUVA; SYSTEMIC THERAPY; THERAPY EFFECT; UNITED STATES; AMBULATORY CARE; COMPARATIVE STUDY; COST; COST BENEFIT ANALYSIS; DIAGNOSTIC PROCEDURE; DRUG APPROVAL; DRUG COST; ECONOMICS; HEALTH CARE COST; PHOTOCHEMOTHERAPY; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CLINICAL LABORATORY TECHNIQUES; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DRUG APPROVAL; DRUG COSTS; HEALTH CARE COSTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OFFICE VISITS; PHOTOCHEMOTHERAPY; PSORIASIS; PUVA THERAPY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; ULTRAVIOLET THERAPY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84929518696     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.11.028     Document Type: Article

References (29)

1. A.A. Nelson, D.J. Pearce, A.B. Fleischer Jr., R. Balkrishnan, and S.R. Feldman Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period J Am Acad Dermatol 58 2008 125 135
2. J.P. Staidle, T.S. Dabade, and S.R. Feldman A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency Expert Opin Pharmacother 12 2011 2041 2054
3. J.F. Fowler, M.S. Duh, and L. Rovba The impact of psoriasis on health care costs and patient work loss J Am Acad Dermatol 59 2008 772 780
4. T. Bhutani, J.W. Wong, B.F. Bebo, and A.W. Armstrong Access to health care in patients with psoriasis and psoriatic arthritis: data from National Psoriasis Foundation survey panels JAMA Dermatol 149 2013 717 721
5. V. Beyer, and S.E. Wolverton Recent trends in systemic psoriasis treatment costs Arch Dermatol 146 2010 46 54
6. I.H. Kim, C.E. West, S.G. Kwatra, S.R. Feldman, and J.L. O'Neill Comparative efficacy of biologics in psoriasis: a review Am J Clin Dermatol 13 2012 365 374
7. K. Kragballe, C.T. Jansén, and J.M. Geiger A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study Acta Derm Venereol 69 1989 35 40
8. H.E. Murray, A.W. Anhalt, and R. Lessard A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study J Am Acad Dermatol 24 1991 598 602
9. J. De Korte, F.M. Mombers, M.A. Sprangers, and J.D. Bos The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review Arch Dermatol 138 2002 1221 1227
10. F. Almutawa, N. Alnomair, Y. Wang, I. Hamzavi, and H.W. Lim Systematic review of UV-based therapy for psoriasis Am J Clin Dermatol 14 2013 87 109
11. S.P. Sivanesan, S. Gattu, and J. Hong Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks J Am Acad Dermatol 61 2009 793 798
12. V.M. Heydendael, P.I. Spuls, and B.C. Opmeer Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis N Engl J Med 349 2003 658 665
13. J.H. Saurat, G. Stingl, and L. Dubertret Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs.placebo in patients with psoriasis (CHAMPION) Br J Dermatol 158 2008 558 566
14. J. Barker, M. Hoffmann, and G. Wozel Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1) Br J Dermatol 165 2011 1109 1117
15. C.L. Leonardi, J.L. Powers, and R.T. Matheson Etanercept as monotherapy in patients with psoriasis N Engl J Med 349 2003 2014 2022
16. A.B. Gottlieb, R.T. Matheson, and N. Lowe A randomized trial of etanercept as monotherapy for psoriasis Arch Dermatol 139 2003 1627 1632
17. K.A. Papp, S. Tyring, and M. Lahfa A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Br J Dermatol 152 2005 1304 1312
18. S. Tyring, A. Gottlieb, and K. Papp Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial Lancet 367 2006 29 35
19. C.E. Griffiths, B.E. Strober, and P. van de Kerkhof Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis N Engl J Med 362 2010 118 128
20. P.J. Mease, D.D. Gladman, and C.T. Ritchlin Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial Arthritis Rheum 52 2005 3279 3289
21. K.B. Gordon, R.G. Langley, and C. Leonardi Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study J Am Acad Dermatol 55 2006 598 606
22. A. Menter, S.K. Tyring, and K. Gordon Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial J Am Acad Dermatol 58 2008 106 115
23. A.B. Gottlieb, R. Evans, and S. Li Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial J Am Acad Dermatol 51 2004 534 542
24. K. Reich, F.O. Nestle, and K. Papp Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial Lancet 366 2005 1367 1374
25. A. Menter, S.R. Feldman, and G.D. Weinstein A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis J Am Acad Dermatol 56 2007 31.e1 31.e15
26. H. Torii, and H. Nakagawa Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial J Dermatol Sci 59 2010 40 49
27. C.L. Leonardi, A.B. Kimball, and K.A. Papp Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 371 2008 1665 1674
28. K.A. Papp, R.G. Langley, and M. Lebwohl Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 371 2008 1675 1684
29. T.F. Tsai, J.C. Ho, and M. Song Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL) J Dermatol Sci 63 2011 154 163